nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRD1—epilepsy syndrome	0.234	0.506	CbGaD
Naltrexone—OPRM1—epilepsy syndrome	0.179	0.387	CbGaD
Naltrexone—UGT1A1—Propofol—epilepsy syndrome	0.08	0.336	CbGbCtD
Naltrexone—ABCB1—epilepsy syndrome	0.0495	0.107	CbGaD
Naltrexone—ABCB1—Levetiracetam—epilepsy syndrome	0.033	0.139	CbGbCtD
Naltrexone—ABCB1—Clobazam—epilepsy syndrome	0.0229	0.096	CbGbCtD
Naltrexone—ABCB1—Lamotrigine—epilepsy syndrome	0.022	0.0924	CbGbCtD
Naltrexone—ABCB1—Carbamazepine—epilepsy syndrome	0.019	0.0795	CbGbCtD
Naltrexone—ABCB1—Phenytoin—epilepsy syndrome	0.017	0.0714	CbGbCtD
Naltrexone—ABCB1—Phenobarbital—epilepsy syndrome	0.0152	0.0636	CbGbCtD
Naltrexone—ABCB1—Midazolam—epilepsy syndrome	0.015	0.0627	CbGbCtD
Naltrexone—ABCB1—Diazepam—epilepsy syndrome	0.0144	0.0603	CbGbCtD
Naltrexone—OPRM1—telencephalic ventricle—epilepsy syndrome	0.00318	0.133	CbGeAlD
Naltrexone—OPRD1—ganglion—epilepsy syndrome	0.0029	0.122	CbGeAlD
Naltrexone—OPRM1—ganglion—epilepsy syndrome	0.00198	0.083	CbGeAlD
Naltrexone—OPRD1—forebrain—epilepsy syndrome	0.00122	0.051	CbGeAlD
Naltrexone—OPRK1—forebrain—epilepsy syndrome	0.00117	0.0489	CbGeAlD
Naltrexone—OPRD1—telencephalon—epilepsy syndrome	0.00112	0.0469	CbGeAlD
Naltrexone—OPRM1—brainstem—epilepsy syndrome	0.00086	0.0361	CbGeAlD
Naltrexone—OPRM1—forebrain—epilepsy syndrome	0.00083	0.0348	CbGeAlD
Naltrexone—OPRM1—telencephalon—epilepsy syndrome	0.000764	0.032	CbGeAlD
Naltrexone—OPRD1—head—epilepsy syndrome	0.000697	0.0292	CbGeAlD
Naltrexone—OPRK1—head—epilepsy syndrome	0.000668	0.028	CbGeAlD
Naltrexone—OPRD1—nervous system—epilepsy syndrome	0.000661	0.0277	CbGeAlD
Naltrexone—OPRD1—central nervous system—epilepsy syndrome	0.000636	0.0267	CbGeAlD
Naltrexone—OPRK1—nervous system—epilepsy syndrome	0.000634	0.0266	CbGeAlD
Naltrexone—OPRK1—central nervous system—epilepsy syndrome	0.00061	0.0256	CbGeAlD
Naltrexone—OPRK1—cerebellum—epilepsy syndrome	0.000596	0.025	CbGeAlD
Naltrexone—OPRM1—midbrain—epilepsy syndrome	0.000548	0.023	CbGeAlD
Naltrexone—OPRM1—spinal cord—epilepsy syndrome	0.000535	0.0224	CbGeAlD
Naltrexone—OPRD1—brain—epilepsy syndrome	0.000505	0.0212	CbGeAlD
Naltrexone—OPRK1—brain—epilepsy syndrome	0.000484	0.0203	CbGeAlD
Naltrexone—OPRM1—head—epilepsy syndrome	0.000475	0.0199	CbGeAlD
Naltrexone—OPRM1—nervous system—epilepsy syndrome	0.000451	0.0189	CbGeAlD
Naltrexone—OPRM1—central nervous system—epilepsy syndrome	0.000434	0.0182	CbGeAlD
Naltrexone—Butorphanol—OPRD1—epilepsy syndrome	0.000347	0.0699	CrCbGaD
Naltrexone—OPRM1—brain—epilepsy syndrome	0.000345	0.0144	CbGeAlD
Naltrexone—Nalbuphine—OPRD1—epilepsy syndrome	0.000317	0.064	CrCbGaD
Naltrexone—Butorphanol—OPRM1—epilepsy syndrome	0.000265	0.0535	CrCbGaD
Naltrexone—Methylnaltrexone—OPRM1—epilepsy syndrome	0.000265	0.0535	CrCbGaD
Naltrexone—Oxymorphone—OPRD1—epilepsy syndrome	0.000258	0.0522	CrCbGaD
Naltrexone—Nalbuphine—OPRM1—epilepsy syndrome	0.000243	0.049	CrCbGaD
Naltrexone—ABCB1—forebrain—epilepsy syndrome	0.000239	0.01	CbGeAlD
Naltrexone—Naloxone—SLCO1A2—epilepsy syndrome	0.000227	0.0457	CrCbGaD
Naltrexone—Hydrocodone—OPRD1—epilepsy syndrome	0.000226	0.0456	CrCbGaD
Naltrexone—ABCB1—telencephalon—epilepsy syndrome	0.00022	0.00923	CbGeAlD
Naltrexone—Oxycodone—OPRD1—epilepsy syndrome	0.000206	0.0416	CrCbGaD
Naltrexone—Oxymorphone—OPRM1—epilepsy syndrome	0.000198	0.0399	CrCbGaD
Naltrexone—Buprenorphine—OPRD1—epilepsy syndrome	0.00019	0.0383	CrCbGaD
Naltrexone—Naloxone—OPRD1—epilepsy syndrome	0.000189	0.038	CrCbGaD
Naltrexone—Hydromorphone—OPRD1—epilepsy syndrome	0.000187	0.0378	CrCbGaD
Naltrexone—ABCB1—medulla oblongata—epilepsy syndrome	0.000173	0.00725	CbGeAlD
Naltrexone—Hydrocodone—OPRM1—epilepsy syndrome	0.000173	0.0349	CrCbGaD
Naltrexone—Morphine—OPRD1—epilepsy syndrome	0.000159	0.0321	CrCbGaD
Naltrexone—ABCB1—midbrain—epilepsy syndrome	0.000158	0.00663	CbGeAlD
Naltrexone—Oxycodone—OPRM1—epilepsy syndrome	0.000158	0.0318	CrCbGaD
Naltrexone—ABCB1—spinal cord—epilepsy syndrome	0.000154	0.00647	CbGeAlD
Naltrexone—Buprenorphine—OPRM1—epilepsy syndrome	0.000145	0.0293	CrCbGaD
Naltrexone—Naloxone—OPRM1—epilepsy syndrome	0.000144	0.0291	CrCbGaD
Naltrexone—Hydromorphone—OPRM1—epilepsy syndrome	0.000143	0.0289	CrCbGaD
Naltrexone—ABCB1—head—epilepsy syndrome	0.000137	0.00575	CbGeAlD
Naltrexone—ABCB1—nervous system—epilepsy syndrome	0.00013	0.00545	CbGeAlD
Naltrexone—ABCB1—central nervous system—epilepsy syndrome	0.000125	0.00525	CbGeAlD
Naltrexone—ABCB1—cerebellum—epilepsy syndrome	0.000122	0.00513	CbGeAlD
Naltrexone—Morphine—OPRM1—epilepsy syndrome	0.000122	0.0246	CrCbGaD
Naltrexone—Methylnaltrexone—CYP2D6—epilepsy syndrome	0.000103	0.0207	CrCbGaD
Naltrexone—ABCB1—brain—epilepsy syndrome	9.94e-05	0.00416	CbGeAlD
Naltrexone—Buprenorphine—ABCG2—epilepsy syndrome	9.65e-05	0.0195	CrCbGaD
Naltrexone—Oxymorphone—CYP2D6—epilepsy syndrome	7.66e-05	0.0155	CrCbGaD
Naltrexone—Buprenorphine—CYP2C19—epilepsy syndrome	7.59e-05	0.0153	CrCbGaD
Naltrexone—Hydrocodone—CYP2D6—epilepsy syndrome	6.69e-05	0.0135	CrCbGaD
Naltrexone—Oxycodone—CYP2D6—epilepsy syndrome	6.11e-05	0.0123	CrCbGaD
Naltrexone—Buprenorphine—CYP2D6—epilepsy syndrome	5.63e-05	0.0114	CrCbGaD
Naltrexone—Hydromorphone—CYP2D6—epilepsy syndrome	5.55e-05	0.0112	CrCbGaD
Naltrexone—Morphine—CYP2D6—epilepsy syndrome	4.72e-05	0.00952	CrCbGaD
Naltrexone—Naloxone—ALB—epilepsy syndrome	4.18e-05	0.00843	CrCbGaD
Naltrexone—Buprenorphine—ABCB1—epilepsy syndrome	4.02e-05	0.00811	CrCbGaD
Naltrexone—Naloxone—ABCB1—epilepsy syndrome	3.99e-05	0.00805	CrCbGaD
Naltrexone—Vision blurred—Gabapentin—epilepsy syndrome	3.52e-05	0.000183	CcSEcCtD
Naltrexone—Headache—Vigabatrin—epilepsy syndrome	3.52e-05	0.000183	CcSEcCtD
Naltrexone—Hypertension—Pregabalin—epilepsy syndrome	3.52e-05	0.000183	CcSEcCtD
Naltrexone—Vomiting—Diazepam—epilepsy syndrome	3.52e-05	0.000183	CcSEcCtD
Naltrexone—Anorexia—Valproic Acid—epilepsy syndrome	3.51e-05	0.000183	CcSEcCtD
Naltrexone—Tremor—Gabapentin—epilepsy syndrome	3.5e-05	0.000182	CcSEcCtD
Naltrexone—Rash—Diazepam—epilepsy syndrome	3.49e-05	0.000182	CcSEcCtD
Naltrexone—Dermatitis—Diazepam—epilepsy syndrome	3.49e-05	0.000182	CcSEcCtD
Naltrexone—Myalgia—Pregabalin—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Arthralgia—Pregabalin—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Chest pain—Pregabalin—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Ill-defined disorder—Gabapentin—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Dizziness—Zonisamide—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Headache—Diazepam—epilepsy syndrome	3.47e-05	0.000181	CcSEcCtD
Naltrexone—Anxiety—Pregabalin—epilepsy syndrome	3.46e-05	0.00018	CcSEcCtD
Naltrexone—Diarrhoea—Clonazepam—epilepsy syndrome	3.46e-05	0.00018	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.45e-05	0.00018	CcSEcCtD
Naltrexone—Asthenia—Carbamazepine—epilepsy syndrome	3.44e-05	0.000179	CcSEcCtD
Naltrexone—Agitation—Gabapentin—epilepsy syndrome	3.43e-05	0.000179	CcSEcCtD
Naltrexone—Diarrhoea—Phenytoin—epilepsy syndrome	3.43e-05	0.000179	CcSEcCtD
Naltrexone—Discomfort—Pregabalin—epilepsy syndrome	3.43e-05	0.000179	CcSEcCtD
Naltrexone—Nausea—Fosphenytoin—epilepsy syndrome	3.43e-05	0.000178	CcSEcCtD
Naltrexone—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.42e-05	0.000178	CcSEcCtD
Naltrexone—Angioedema—Gabapentin—epilepsy syndrome	3.42e-05	0.000178	CcSEcCtD
Naltrexone—Hypersensitivity—Lamotrigine—epilepsy syndrome	3.41e-05	0.000178	CcSEcCtD
Naltrexone—Vomiting—Felbamate—epilepsy syndrome	3.41e-05	0.000177	CcSEcCtD
Naltrexone—Dry mouth—Pregabalin—epilepsy syndrome	3.39e-05	0.000177	CcSEcCtD
Naltrexone—Pruritus—Carbamazepine—epilepsy syndrome	3.39e-05	0.000177	CcSEcCtD
Naltrexone—Rash—Felbamate—epilepsy syndrome	3.38e-05	0.000176	CcSEcCtD
Naltrexone—Eye disorder—Topiramate—epilepsy syndrome	3.38e-05	0.000176	CcSEcCtD
Naltrexone—Dermatitis—Felbamate—epilepsy syndrome	3.37e-05	0.000176	CcSEcCtD
Naltrexone—Malaise—Gabapentin—epilepsy syndrome	3.37e-05	0.000176	CcSEcCtD
Naltrexone—Tinnitus—Topiramate—epilepsy syndrome	3.37e-05	0.000175	CcSEcCtD
Naltrexone—Morphine—ABCB1—epilepsy syndrome	3.37e-05	0.00679	CrCbGaD
Naltrexone—Headache—Felbamate—epilepsy syndrome	3.36e-05	0.000175	CcSEcCtD
Naltrexone—Confusional state—Pregabalin—epilepsy syndrome	3.35e-05	0.000175	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.35e-05	0.000175	CcSEcCtD
Naltrexone—Cardiac disorder—Topiramate—epilepsy syndrome	3.35e-05	0.000175	CcSEcCtD
Naltrexone—Syncope—Gabapentin—epilepsy syndrome	3.35e-05	0.000175	CcSEcCtD
Naltrexone—Dizziness—Clonazepam—epilepsy syndrome	3.34e-05	0.000174	CcSEcCtD
Naltrexone—Nausea—Vigabatrin—epilepsy syndrome	3.34e-05	0.000174	CcSEcCtD
Naltrexone—Vomiting—Zonisamide—epilepsy syndrome	3.33e-05	0.000174	CcSEcCtD
Naltrexone—Insomnia—Valproic Acid—epilepsy syndrome	3.33e-05	0.000173	CcSEcCtD
Naltrexone—Oedema—Pregabalin—epilepsy syndrome	3.33e-05	0.000173	CcSEcCtD
Naltrexone—Anaphylactic shock—Pregabalin—epilepsy syndrome	3.33e-05	0.000173	CcSEcCtD
Naltrexone—Asthenia—Lamotrigine—epilepsy syndrome	3.32e-05	0.000173	CcSEcCtD
Naltrexone—Dizziness—Phenytoin—epilepsy syndrome	3.32e-05	0.000173	CcSEcCtD
Naltrexone—Rash—Zonisamide—epilepsy syndrome	3.31e-05	0.000172	CcSEcCtD
Naltrexone—Infection—Pregabalin—epilepsy syndrome	3.31e-05	0.000172	CcSEcCtD
Naltrexone—Paraesthesia—Valproic Acid—epilepsy syndrome	3.3e-05	0.000172	CcSEcCtD
Naltrexone—Palpitations—Gabapentin—epilepsy syndrome	3.3e-05	0.000172	CcSEcCtD
Naltrexone—Dermatitis—Zonisamide—epilepsy syndrome	3.3e-05	0.000172	CcSEcCtD
Naltrexone—Dizziness—Oxcarbazepine—epilepsy syndrome	3.3e-05	0.000172	CcSEcCtD
Naltrexone—Nausea—Diazepam—epilepsy syndrome	3.29e-05	0.000171	CcSEcCtD
Naltrexone—Loss of consciousness—Gabapentin—epilepsy syndrome	3.29e-05	0.000171	CcSEcCtD
Naltrexone—Headache—Zonisamide—epilepsy syndrome	3.28e-05	0.000171	CcSEcCtD
Naltrexone—Dyspnoea—Valproic Acid—epilepsy syndrome	3.28e-05	0.000171	CcSEcCtD
Naltrexone—Diarrhoea—Carbamazepine—epilepsy syndrome	3.28e-05	0.000171	CcSEcCtD
Naltrexone—Angiopathy—Topiramate—epilepsy syndrome	3.28e-05	0.000171	CcSEcCtD
Naltrexone—Pruritus—Lamotrigine—epilepsy syndrome	3.28e-05	0.000171	CcSEcCtD
Naltrexone—Shock—Pregabalin—epilepsy syndrome	3.27e-05	0.00017	CcSEcCtD
Naltrexone—Somnolence—Valproic Acid—epilepsy syndrome	3.27e-05	0.00017	CcSEcCtD
Naltrexone—Immune system disorder—Topiramate—epilepsy syndrome	3.26e-05	0.00017	CcSEcCtD
Naltrexone—Nervous system disorder—Pregabalin—epilepsy syndrome	3.26e-05	0.00017	CcSEcCtD
Naltrexone—Cough—Gabapentin—epilepsy syndrome	3.26e-05	0.00017	CcSEcCtD
Naltrexone—Mediastinal disorder—Topiramate—epilepsy syndrome	3.26e-05	0.00017	CcSEcCtD
Naltrexone—Tachycardia—Pregabalin—epilepsy syndrome	3.25e-05	0.000169	CcSEcCtD
Naltrexone—Chills—Topiramate—epilepsy syndrome	3.24e-05	0.000169	CcSEcCtD
Naltrexone—Convulsion—Gabapentin—epilepsy syndrome	3.24e-05	0.000169	CcSEcCtD
Naltrexone—Skin disorder—Pregabalin—epilepsy syndrome	3.23e-05	0.000168	CcSEcCtD
Naltrexone—Hypertension—Gabapentin—epilepsy syndrome	3.23e-05	0.000168	CcSEcCtD
Naltrexone—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.22e-05	0.000168	CcSEcCtD
Naltrexone—Vomiting—Clonazepam—epilepsy syndrome	3.21e-05	0.000167	CcSEcCtD
Naltrexone—Decreased appetite—Valproic Acid—epilepsy syndrome	3.2e-05	0.000167	CcSEcCtD
Naltrexone—Alopecia—Topiramate—epilepsy syndrome	3.19e-05	0.000166	CcSEcCtD
Naltrexone—Vomiting—Phenytoin—epilepsy syndrome	3.19e-05	0.000166	CcSEcCtD
Naltrexone—Rash—Clonazepam—epilepsy syndrome	3.19e-05	0.000166	CcSEcCtD
Naltrexone—Dermatitis—Clonazepam—epilepsy syndrome	3.18e-05	0.000166	CcSEcCtD
Naltrexone—Chest pain—Gabapentin—epilepsy syndrome	3.18e-05	0.000166	CcSEcCtD
Naltrexone—Arthralgia—Gabapentin—epilepsy syndrome	3.18e-05	0.000166	CcSEcCtD
Naltrexone—Myalgia—Gabapentin—epilepsy syndrome	3.18e-05	0.000166	CcSEcCtD
Naltrexone—Nausea—Felbamate—epilepsy syndrome	3.18e-05	0.000166	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.18e-05	0.000165	CcSEcCtD
Naltrexone—Vomiting—Oxcarbazepine—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Fatigue—Valproic Acid—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Anxiety—Gabapentin—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Anorexia—Pregabalin—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Dizziness—Carbamazepine—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Diarrhoea—Lamotrigine—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Headache—Clonazepam—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Rash—Phenytoin—epilepsy syndrome	3.17e-05	0.000165	CcSEcCtD
Naltrexone—Mental disorder—Topiramate—epilepsy syndrome	3.16e-05	0.000165	CcSEcCtD
Naltrexone—Dermatitis—Phenytoin—epilepsy syndrome	3.16e-05	0.000165	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.16e-05	0.000165	CcSEcCtD
Naltrexone—Rash—Oxcarbazepine—epilepsy syndrome	3.15e-05	0.000164	CcSEcCtD
Naltrexone—Pain—Valproic Acid—epilepsy syndrome	3.15e-05	0.000164	CcSEcCtD
Naltrexone—Constipation—Valproic Acid—epilepsy syndrome	3.15e-05	0.000164	CcSEcCtD
Naltrexone—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.15e-05	0.000164	CcSEcCtD
Naltrexone—Headache—Phenytoin—epilepsy syndrome	3.14e-05	0.000164	CcSEcCtD
Naltrexone—Malnutrition—Topiramate—epilepsy syndrome	3.14e-05	0.000164	CcSEcCtD
Naltrexone—Discomfort—Gabapentin—epilepsy syndrome	3.14e-05	0.000164	CcSEcCtD
Naltrexone—Headache—Oxcarbazepine—epilepsy syndrome	3.13e-05	0.000163	CcSEcCtD
Naltrexone—Nausea—Zonisamide—epilepsy syndrome	3.11e-05	0.000162	CcSEcCtD
Naltrexone—Dry mouth—Gabapentin—epilepsy syndrome	3.11e-05	0.000162	CcSEcCtD
Naltrexone—Flatulence—Topiramate—epilepsy syndrome	3.1e-05	0.000161	CcSEcCtD
Naltrexone—Tension—Topiramate—epilepsy syndrome	3.09e-05	0.000161	CcSEcCtD
Naltrexone—Dysgeusia—Topiramate—epilepsy syndrome	3.08e-05	0.00016	CcSEcCtD
Naltrexone—Confusional state—Gabapentin—epilepsy syndrome	3.08e-05	0.00016	CcSEcCtD
Naltrexone—Dizziness—Lamotrigine—epilepsy syndrome	3.06e-05	0.00016	CcSEcCtD
Naltrexone—Nervousness—Topiramate—epilepsy syndrome	3.05e-05	0.000159	CcSEcCtD
Naltrexone—Anaphylactic shock—Gabapentin—epilepsy syndrome	3.05e-05	0.000159	CcSEcCtD
Naltrexone—Oedema—Gabapentin—epilepsy syndrome	3.05e-05	0.000159	CcSEcCtD
Naltrexone—Vomiting—Carbamazepine—epilepsy syndrome	3.05e-05	0.000159	CcSEcCtD
Naltrexone—Back pain—Topiramate—epilepsy syndrome	3.04e-05	0.000158	CcSEcCtD
Naltrexone—Feeling abnormal—Valproic Acid—epilepsy syndrome	3.03e-05	0.000158	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.03e-05	0.000158	CcSEcCtD
Naltrexone—Infection—Gabapentin—epilepsy syndrome	3.03e-05	0.000158	CcSEcCtD
Naltrexone—Muscle spasms—Topiramate—epilepsy syndrome	3.02e-05	0.000157	CcSEcCtD
Naltrexone—Rash—Carbamazepine—epilepsy syndrome	3.02e-05	0.000157	CcSEcCtD
Naltrexone—Dermatitis—Carbamazepine—epilepsy syndrome	3.02e-05	0.000157	CcSEcCtD
Naltrexone—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.01e-05	0.000157	CcSEcCtD
Naltrexone—Insomnia—Pregabalin—epilepsy syndrome	3.01e-05	0.000157	CcSEcCtD
Naltrexone—Nausea—Clonazepam—epilepsy syndrome	3e-05	0.000156	CcSEcCtD
Naltrexone—Headache—Carbamazepine—epilepsy syndrome	3e-05	0.000156	CcSEcCtD
Naltrexone—Shock—Gabapentin—epilepsy syndrome	3e-05	0.000156	CcSEcCtD
Naltrexone—Nervous system disorder—Gabapentin—epilepsy syndrome	2.99e-05	0.000156	CcSEcCtD
Naltrexone—Paraesthesia—Pregabalin—epilepsy syndrome	2.99e-05	0.000156	CcSEcCtD
Naltrexone—Nausea—Phenytoin—epilepsy syndrome	2.98e-05	0.000155	CcSEcCtD
Naltrexone—Tachycardia—Gabapentin—epilepsy syndrome	2.98e-05	0.000155	CcSEcCtD
Naltrexone—Dyspnoea—Pregabalin—epilepsy syndrome	2.97e-05	0.000154	CcSEcCtD
Naltrexone—Nausea—Oxcarbazepine—epilepsy syndrome	2.97e-05	0.000154	CcSEcCtD
Naltrexone—Vision blurred—Topiramate—epilepsy syndrome	2.96e-05	0.000154	CcSEcCtD
Naltrexone—Skin disorder—Gabapentin—epilepsy syndrome	2.96e-05	0.000154	CcSEcCtD
Naltrexone—Somnolence—Pregabalin—epilepsy syndrome	2.96e-05	0.000154	CcSEcCtD
Naltrexone—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.95e-05	0.000154	CcSEcCtD
Naltrexone—Tremor—Topiramate—epilepsy syndrome	2.95e-05	0.000153	CcSEcCtD
Naltrexone—Vomiting—Lamotrigine—epilepsy syndrome	2.94e-05	0.000153	CcSEcCtD
Naltrexone—Urticaria—Valproic Acid—epilepsy syndrome	2.92e-05	0.000152	CcSEcCtD
Naltrexone—Rash—Lamotrigine—epilepsy syndrome	2.92e-05	0.000152	CcSEcCtD
Naltrexone—Ill-defined disorder—Topiramate—epilepsy syndrome	2.92e-05	0.000152	CcSEcCtD
Naltrexone—Dermatitis—Lamotrigine—epilepsy syndrome	2.92e-05	0.000152	CcSEcCtD
Naltrexone—Abdominal pain—Valproic Acid—epilepsy syndrome	2.91e-05	0.000152	CcSEcCtD
Naltrexone—Body temperature increased—Valproic Acid—epilepsy syndrome	2.91e-05	0.000152	CcSEcCtD
Naltrexone—Anorexia—Gabapentin—epilepsy syndrome	2.91e-05	0.000151	CcSEcCtD
Naltrexone—Headache—Lamotrigine—epilepsy syndrome	2.9e-05	0.000151	CcSEcCtD
Naltrexone—Decreased appetite—Pregabalin—epilepsy syndrome	2.89e-05	0.000151	CcSEcCtD
Naltrexone—Agitation—Topiramate—epilepsy syndrome	2.89e-05	0.000151	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.87e-05	0.00015	CcSEcCtD
Naltrexone—Fatigue—Pregabalin—epilepsy syndrome	2.87e-05	0.000149	CcSEcCtD
Naltrexone—Nausea—Carbamazepine—epilepsy syndrome	2.85e-05	0.000148	CcSEcCtD
Naltrexone—Constipation—Pregabalin—epilepsy syndrome	2.84e-05	0.000148	CcSEcCtD
Naltrexone—Pain—Pregabalin—epilepsy syndrome	2.84e-05	0.000148	CcSEcCtD
Naltrexone—Malaise—Topiramate—epilepsy syndrome	2.84e-05	0.000148	CcSEcCtD
Naltrexone—Syncope—Topiramate—epilepsy syndrome	2.82e-05	0.000147	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.78e-05	0.000145	CcSEcCtD
Naltrexone—Palpitations—Topiramate—epilepsy syndrome	2.78e-05	0.000145	CcSEcCtD
Naltrexone—Loss of consciousness—Topiramate—epilepsy syndrome	2.76e-05	0.000144	CcSEcCtD
Naltrexone—Insomnia—Gabapentin—epilepsy syndrome	2.76e-05	0.000144	CcSEcCtD
Naltrexone—Nausea—Lamotrigine—epilepsy syndrome	2.75e-05	0.000143	CcSEcCtD
Naltrexone—Cough—Topiramate—epilepsy syndrome	2.74e-05	0.000143	CcSEcCtD
Naltrexone—Feeling abnormal—Pregabalin—epilepsy syndrome	2.74e-05	0.000143	CcSEcCtD
Naltrexone—Paraesthesia—Gabapentin—epilepsy syndrome	2.74e-05	0.000143	CcSEcCtD
Naltrexone—Convulsion—Topiramate—epilepsy syndrome	2.72e-05	0.000142	CcSEcCtD
Naltrexone—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.72e-05	0.000142	CcSEcCtD
Naltrexone—Dyspnoea—Gabapentin—epilepsy syndrome	2.72e-05	0.000142	CcSEcCtD
Naltrexone—Hypertension—Topiramate—epilepsy syndrome	2.72e-05	0.000141	CcSEcCtD
Naltrexone—Somnolence—Gabapentin—epilepsy syndrome	2.71e-05	0.000141	CcSEcCtD
Naltrexone—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.71e-05	0.000141	CcSEcCtD
Naltrexone—Myalgia—Topiramate—epilepsy syndrome	2.68e-05	0.000139	CcSEcCtD
Naltrexone—Chest pain—Topiramate—epilepsy syndrome	2.68e-05	0.000139	CcSEcCtD
Naltrexone—Arthralgia—Topiramate—epilepsy syndrome	2.68e-05	0.000139	CcSEcCtD
Naltrexone—Anxiety—Topiramate—epilepsy syndrome	2.67e-05	0.000139	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.66e-05	0.000138	CcSEcCtD
Naltrexone—Decreased appetite—Gabapentin—epilepsy syndrome	2.65e-05	0.000138	CcSEcCtD
Naltrexone—Discomfort—Topiramate—epilepsy syndrome	2.65e-05	0.000138	CcSEcCtD
Naltrexone—Urticaria—Pregabalin—epilepsy syndrome	2.64e-05	0.000138	CcSEcCtD
Naltrexone—Asthenia—Valproic Acid—epilepsy syndrome	2.64e-05	0.000138	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.63e-05	0.000137	CcSEcCtD
Naltrexone—Fatigue—Gabapentin—epilepsy syndrome	2.63e-05	0.000137	CcSEcCtD
Naltrexone—Abdominal pain—Pregabalin—epilepsy syndrome	2.63e-05	0.000137	CcSEcCtD
Naltrexone—Body temperature increased—Pregabalin—epilepsy syndrome	2.63e-05	0.000137	CcSEcCtD
Naltrexone—Dry mouth—Topiramate—epilepsy syndrome	2.62e-05	0.000136	CcSEcCtD
Naltrexone—Pain—Gabapentin—epilepsy syndrome	2.61e-05	0.000136	CcSEcCtD
Naltrexone—Constipation—Gabapentin—epilepsy syndrome	2.61e-05	0.000136	CcSEcCtD
Naltrexone—Pruritus—Valproic Acid—epilepsy syndrome	2.6e-05	0.000136	CcSEcCtD
Naltrexone—Confusional state—Topiramate—epilepsy syndrome	2.59e-05	0.000135	CcSEcCtD
Naltrexone—Oedema—Topiramate—epilepsy syndrome	2.57e-05	0.000134	CcSEcCtD
Naltrexone—Infection—Topiramate—epilepsy syndrome	2.55e-05	0.000133	CcSEcCtD
Naltrexone—Shock—Topiramate—epilepsy syndrome	2.53e-05	0.000132	CcSEcCtD
Naltrexone—Diarrhoea—Valproic Acid—epilepsy syndrome	2.52e-05	0.000131	CcSEcCtD
Naltrexone—Nervous system disorder—Topiramate—epilepsy syndrome	2.52e-05	0.000131	CcSEcCtD
Naltrexone—Feeling abnormal—Gabapentin—epilepsy syndrome	2.51e-05	0.000131	CcSEcCtD
Naltrexone—Tachycardia—Topiramate—epilepsy syndrome	2.5e-05	0.00013	CcSEcCtD
Naltrexone—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.49e-05	0.00013	CcSEcCtD
Naltrexone—Skin disorder—Topiramate—epilepsy syndrome	2.49e-05	0.00013	CcSEcCtD
Naltrexone—Hyperhidrosis—Topiramate—epilepsy syndrome	2.48e-05	0.000129	CcSEcCtD
Naltrexone—Hypersensitivity—Pregabalin—epilepsy syndrome	2.45e-05	0.000128	CcSEcCtD
Naltrexone—Anorexia—Topiramate—epilepsy syndrome	2.45e-05	0.000127	CcSEcCtD
Naltrexone—Dizziness—Valproic Acid—epilepsy syndrome	2.43e-05	0.000127	CcSEcCtD
Naltrexone—Urticaria—Gabapentin—epilepsy syndrome	2.42e-05	0.000126	CcSEcCtD
Naltrexone—Abdominal pain—Gabapentin—epilepsy syndrome	2.41e-05	0.000126	CcSEcCtD
Naltrexone—Body temperature increased—Gabapentin—epilepsy syndrome	2.41e-05	0.000126	CcSEcCtD
Naltrexone—Asthenia—Pregabalin—epilepsy syndrome	2.39e-05	0.000124	CcSEcCtD
Naltrexone—Pruritus—Pregabalin—epilepsy syndrome	2.35e-05	0.000123	CcSEcCtD
Naltrexone—Vomiting—Valproic Acid—epilepsy syndrome	2.34e-05	0.000122	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.34e-05	0.000122	CcSEcCtD
Naltrexone—Insomnia—Topiramate—epilepsy syndrome	2.32e-05	0.000121	CcSEcCtD
Naltrexone—Rash—Valproic Acid—epilepsy syndrome	2.32e-05	0.000121	CcSEcCtD
Naltrexone—Dermatitis—Valproic Acid—epilepsy syndrome	2.32e-05	0.000121	CcSEcCtD
Naltrexone—Headache—Valproic Acid—epilepsy syndrome	2.31e-05	0.00012	CcSEcCtD
Naltrexone—Paraesthesia—Topiramate—epilepsy syndrome	2.3e-05	0.00012	CcSEcCtD
Naltrexone—Dyspnoea—Topiramate—epilepsy syndrome	2.29e-05	0.000119	CcSEcCtD
Naltrexone—Somnolence—Topiramate—epilepsy syndrome	2.28e-05	0.000119	CcSEcCtD
Naltrexone—Diarrhoea—Pregabalin—epilepsy syndrome	2.28e-05	0.000119	CcSEcCtD
Naltrexone—Hypersensitivity—Gabapentin—epilepsy syndrome	2.25e-05	0.000117	CcSEcCtD
Naltrexone—Decreased appetite—Topiramate—epilepsy syndrome	2.23e-05	0.000116	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.22e-05	0.000115	CcSEcCtD
Naltrexone—Fatigue—Topiramate—epilepsy syndrome	2.21e-05	0.000115	CcSEcCtD
Naltrexone—Dizziness—Pregabalin—epilepsy syndrome	2.2e-05	0.000115	CcSEcCtD
Naltrexone—Pain—Topiramate—epilepsy syndrome	2.19e-05	0.000114	CcSEcCtD
Naltrexone—Constipation—Topiramate—epilepsy syndrome	2.19e-05	0.000114	CcSEcCtD
Naltrexone—Asthenia—Gabapentin—epilepsy syndrome	2.19e-05	0.000114	CcSEcCtD
Naltrexone—Nausea—Valproic Acid—epilepsy syndrome	2.19e-05	0.000114	CcSEcCtD
Naltrexone—Pruritus—Gabapentin—epilepsy syndrome	2.16e-05	0.000112	CcSEcCtD
Naltrexone—Vomiting—Pregabalin—epilepsy syndrome	2.12e-05	0.00011	CcSEcCtD
Naltrexone—Feeling abnormal—Topiramate—epilepsy syndrome	2.11e-05	0.00011	CcSEcCtD
Naltrexone—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.1e-05	0.000109	CcSEcCtD
Naltrexone—Rash—Pregabalin—epilepsy syndrome	2.1e-05	0.000109	CcSEcCtD
Naltrexone—Dermatitis—Pregabalin—epilepsy syndrome	2.1e-05	0.000109	CcSEcCtD
Naltrexone—Diarrhoea—Gabapentin—epilepsy syndrome	2.09e-05	0.000109	CcSEcCtD
Naltrexone—Headache—Pregabalin—epilepsy syndrome	2.08e-05	0.000109	CcSEcCtD
Naltrexone—Urticaria—Topiramate—epilepsy syndrome	2.04e-05	0.000106	CcSEcCtD
Naltrexone—Abdominal pain—Topiramate—epilepsy syndrome	2.03e-05	0.000106	CcSEcCtD
Naltrexone—Body temperature increased—Topiramate—epilepsy syndrome	2.03e-05	0.000106	CcSEcCtD
Naltrexone—Dizziness—Gabapentin—epilepsy syndrome	2.02e-05	0.000105	CcSEcCtD
Naltrexone—Nausea—Pregabalin—epilepsy syndrome	1.98e-05	0.000103	CcSEcCtD
Naltrexone—Vomiting—Gabapentin—epilepsy syndrome	1.94e-05	0.000101	CcSEcCtD
Naltrexone—Rash—Gabapentin—epilepsy syndrome	1.92e-05	0.0001	CcSEcCtD
Naltrexone—Dermatitis—Gabapentin—epilepsy syndrome	1.92e-05	0.0001	CcSEcCtD
Naltrexone—Headache—Gabapentin—epilepsy syndrome	1.91e-05	9.95e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Topiramate—epilepsy syndrome	1.89e-05	9.85e-05	CcSEcCtD
Naltrexone—Asthenia—Topiramate—epilepsy syndrome	1.84e-05	9.59e-05	CcSEcCtD
Naltrexone—Pruritus—Topiramate—epilepsy syndrome	1.82e-05	9.46e-05	CcSEcCtD
Naltrexone—Nausea—Gabapentin—epilepsy syndrome	1.81e-05	9.44e-05	CcSEcCtD
Naltrexone—Diarrhoea—Topiramate—epilepsy syndrome	1.76e-05	9.15e-05	CcSEcCtD
Naltrexone—Dizziness—Topiramate—epilepsy syndrome	1.7e-05	8.84e-05	CcSEcCtD
Naltrexone—Vomiting—Topiramate—epilepsy syndrome	1.63e-05	8.5e-05	CcSEcCtD
Naltrexone—Rash—Topiramate—epilepsy syndrome	1.62e-05	8.43e-05	CcSEcCtD
Naltrexone—Dermatitis—Topiramate—epilepsy syndrome	1.62e-05	8.42e-05	CcSEcCtD
Naltrexone—Headache—Topiramate—epilepsy syndrome	1.61e-05	8.38e-05	CcSEcCtD
Naltrexone—Nausea—Topiramate—epilepsy syndrome	1.52e-05	7.94e-05	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—NTRK2—epilepsy syndrome	1.15e-05	0.000146	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR2—epilepsy syndrome	1.15e-05	0.000146	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—epilepsy syndrome	1.14e-05	0.000146	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DUSP6—epilepsy syndrome	1.14e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CDC42—epilepsy syndrome	1.13e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRA2A—epilepsy syndrome	1.12e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AGT—epilepsy syndrome	1.12e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GABBR1—epilepsy syndrome	1.12e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLAT—epilepsy syndrome	1.12e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HSPB1—epilepsy syndrome	1.11e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CRH—epilepsy syndrome	1.11e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL3—epilepsy syndrome	1.11e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL2—epilepsy syndrome	1.11e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—OXT—epilepsy syndrome	1.11e-05	0.000142	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD17B4—epilepsy syndrome	1.11e-05	0.000141	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR5—epilepsy syndrome	1.1e-05	0.00014	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AVP—epilepsy syndrome	1.09e-05	0.000139	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—epilepsy syndrome	1.09e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BDKRB2—epilepsy syndrome	1.08e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL12—epilepsy syndrome	1.08e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—POMC—epilepsy syndrome	1.08e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRH3—epilepsy syndrome	1.08e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2A—epilepsy syndrome	1.07e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PRKCB—epilepsy syndrome	1.07e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6ST—epilepsy syndrome	1.07e-05	0.000136	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP2D6—epilepsy syndrome	1.07e-05	0.000136	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPP1R3C—epilepsy syndrome	1.07e-05	0.000136	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GBE1—epilepsy syndrome	1.07e-05	0.000136	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CNR1—epilepsy syndrome	1.06e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUNB—epilepsy syndrome	1.06e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLCB1—epilepsy syndrome	1.06e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.04e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC1—epilepsy syndrome	1.03e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTK2B—epilepsy syndrome	1.03e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR7—epilepsy syndrome	1.03e-05	0.000132	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—epilepsy syndrome	1.03e-05	0.000131	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR5—epilepsy syndrome	1.02e-05	0.00013	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGT—epilepsy syndrome	1.02e-05	0.00013	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADRA2A—epilepsy syndrome	1.02e-05	0.00013	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—BCHE—epilepsy syndrome	1.01e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR2—epilepsy syndrome	1.01e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NTRK2—epilepsy syndrome	1.01e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SST—epilepsy syndrome	1.01e-05	0.000128	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ASAH1—epilepsy syndrome	1e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HBEGF—epilepsy syndrome	1e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR3—epilepsy syndrome	1e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2A—epilepsy syndrome	1e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DUSP6—epilepsy syndrome	9.98e-06	0.000127	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	9.93e-06	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA2A—epilepsy syndrome	9.85e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT3—epilepsy syndrome	9.85e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLAT—epilepsy syndrome	9.81e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—POMC—epilepsy syndrome	9.79e-06	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—STXBP1—epilepsy syndrome	9.77e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NPY—epilepsy syndrome	9.75e-06	0.000124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ATP2A2—epilepsy syndrome	9.75e-06	0.000124	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC2A1—epilepsy syndrome	9.67e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADAM10—epilepsy syndrome	9.62e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL2—epilepsy syndrome	9.57e-06	0.000122	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—epilepsy syndrome	9.57e-06	0.000122	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PLCB1—epilepsy syndrome	9.57e-06	0.000122	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TH—epilepsy syndrome	9.53e-06	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NT5E—epilepsy syndrome	9.52e-06	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALAD—epilepsy syndrome	9.52e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGT—epilepsy syndrome	9.49e-06	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	9.47e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BDKRB2—epilepsy syndrome	9.46e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL12—epilepsy syndrome	9.46e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—POMC—epilepsy syndrome	9.45e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PRKCB—epilepsy syndrome	9.42e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CRH—epilepsy syndrome	9.41e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HSPB1—epilepsy syndrome	9.41e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL2—epilepsy syndrome	9.41e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—OXT—epilepsy syndrome	9.41e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL3—epilepsy syndrome	9.41e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6ST—epilepsy syndrome	9.38e-06	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—epilepsy syndrome	9.29e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUNB—epilepsy syndrome	9.29e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CNR1—epilepsy syndrome	9.29e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR5—epilepsy syndrome	9.28e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLCB1—epilepsy syndrome	9.25e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—S100B—epilepsy syndrome	9.1e-06	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CACNA1A—epilepsy syndrome	9.08e-06	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH7A1—epilepsy syndrome	9.08e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2A—epilepsy syndrome	9.08e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR7—epilepsy syndrome	9.06e-06	0.000115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SOCS3—epilepsy syndrome	9.01e-06	0.000115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDC42—epilepsy syndrome	8.98e-06	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ST3GAL3—epilepsy syndrome	8.89e-06	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HBEGF—epilepsy syndrome	8.8e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PRKCB—epilepsy syndrome	8.77e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTK2B—epilepsy syndrome	8.74e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC1—epilepsy syndrome	8.74e-06	0.000111	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADSL—epilepsy syndrome	8.71e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AVP—epilepsy syndrome	8.7e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT3—epilepsy syndrome	8.63e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGT—epilepsy syndrome	8.62e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—POMC—epilepsy syndrome	8.58e-06	0.000109	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLUL—epilepsy syndrome	8.54e-06	0.000109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SST—epilepsy syndrome	8.51e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK2—epilepsy syndrome	8.51e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR2—epilepsy syndrome	8.51e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADAM10—epilepsy syndrome	8.43e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DUSP6—epilepsy syndrome	8.43e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL2—epilepsy syndrome	8.4e-06	0.000107	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CACNA1D—epilepsy syndrome	8.38e-06	0.000107	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	8.34e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA2A—epilepsy syndrome	8.32e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLAT—epilepsy syndrome	8.29e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HES1—epilepsy syndrome	8.23e-06	0.000105	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	8.12e-06	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FYN—epilepsy syndrome	8e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BDKRB2—epilepsy syndrome	8e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL12—epilepsy syndrome	8e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—POMC—epilepsy syndrome	7.99e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—S100B—epilepsy syndrome	7.98e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—H2AFX—epilepsy syndrome	7.97e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCB—epilepsy syndrome	7.96e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MEF2C—epilepsy syndrome	7.96e-06	0.000101	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—epilepsy syndrome	7.96e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6ST—epilepsy syndrome	7.93e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SOCS3—epilepsy syndrome	7.9e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDC42—epilepsy syndrome	7.88e-06	0.0001	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUNB—epilepsy syndrome	7.85e-06	0.0001	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR1—epilepsy syndrome	7.85e-06	0.0001	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAT—epilepsy syndrome	7.85e-06	0.0001	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TXNRD1—epilepsy syndrome	7.84e-06	9.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLCB1—epilepsy syndrome	7.82e-06	9.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	7.79e-06	9.93e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AVP—epilepsy syndrome	7.72e-06	9.84e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—YWHAZ—epilepsy syndrome	7.69e-06	9.8e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR7—epilepsy syndrome	7.66e-06	9.76e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCB1—epilepsy syndrome	7.64e-06	9.73e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AVP—epilepsy syndrome	7.63e-06	9.72e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AQP1—epilepsy syndrome	7.61e-06	9.7e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGF—epilepsy syndrome	7.6e-06	9.69e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HBEGF—epilepsy syndrome	7.43e-06	9.47e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR5—epilepsy syndrome	7.4e-06	9.42e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT3—epilepsy syndrome	7.3e-06	9.3e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—epilepsy syndrome	7.25e-06	9.24e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—epilepsy syndrome	7.24e-06	9.22e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HES1—epilepsy syndrome	7.21e-06	9.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADAM10—epilepsy syndrome	7.13e-06	9.08e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—epilepsy syndrome	7.1e-06	9.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—epilepsy syndrome	7.1e-06	9.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FYN—epilepsy syndrome	7.01e-06	8.94e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—H2AFX—epilepsy syndrome	6.99e-06	8.91e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MEF2C—epilepsy syndrome	6.98e-06	8.89e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	6.96e-06	8.87e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	6.88e-06	8.77e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CHRM3—epilepsy syndrome	6.88e-06	8.77e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TSC2—epilepsy syndrome	6.88e-06	8.76e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—epilepsy syndrome	6.87e-06	8.75e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—YWHAZ—epilepsy syndrome	6.74e-06	8.59e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S100B—epilepsy syndrome	6.74e-06	8.59e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—epilepsy syndrome	6.73e-06	8.57e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS3—epilepsy syndrome	6.67e-06	8.51e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGF—epilepsy syndrome	6.67e-06	8.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDC42—epilepsy syndrome	6.66e-06	8.48e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—epilepsy syndrome	6.59e-06	8.4e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—epilepsy syndrome	6.49e-06	8.26e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AVP—epilepsy syndrome	6.45e-06	8.21e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—epilepsy syndrome	6.35e-06	8.09e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCB—epilepsy syndrome	6.35e-06	8.09e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6ST—epilepsy syndrome	6.32e-06	8.05e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—epilepsy syndrome	6.22e-06	7.93e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—epilepsy syndrome	6.1e-06	7.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—epilepsy syndrome	6.1e-06	7.77e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC2—epilepsy syndrome	6.03e-06	7.68e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—epilepsy syndrome	6.02e-06	7.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FYN—epilepsy syndrome	5.93e-06	7.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—H2AFX—epilepsy syndrome	5.91e-06	7.53e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—epilepsy syndrome	5.9e-06	7.52e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MEF2C—epilepsy syndrome	5.9e-06	7.51e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—epilepsy syndrome	5.78e-06	7.37e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—epilepsy syndrome	5.78e-06	7.37e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	5.7e-06	7.26e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—epilepsy syndrome	5.66e-06	7.21e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGF—epilepsy syndrome	5.63e-06	7.18e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG2—epilepsy syndrome	5.61e-06	7.15e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCB—epilepsy syndrome	5.56e-06	7.09e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6ST—epilepsy syndrome	5.54e-06	7.06e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—epilepsy syndrome	5.48e-06	6.98e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	5.47e-06	6.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	5.44e-06	6.93e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—epilepsy syndrome	5.36e-06	6.83e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—epilepsy syndrome	5.24e-06	6.68e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	5.18e-06	6.6e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—epilepsy syndrome	5.11e-06	6.51e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC2—epilepsy syndrome	5.1e-06	6.49e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—epilepsy syndrome	5.09e-06	6.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—epilepsy syndrome	5.07e-06	6.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—epilepsy syndrome	4.99e-06	6.35e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—epilepsy syndrome	4.96e-06	6.32e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	4.91e-06	6.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—epilepsy syndrome	4.89e-06	6.23e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—epilepsy syndrome	4.78e-06	6.09e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RELA—epilepsy syndrome	4.75e-06	6.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCB—epilepsy syndrome	4.7e-06	5.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6ST—epilepsy syndrome	4.68e-06	5.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	4.68e-06	5.96e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	4.67e-06	5.95e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—epilepsy syndrome	4.65e-06	5.93e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—epilepsy syndrome	4.65e-06	5.93e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—epilepsy syndrome	4.48e-06	5.71e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	4.44e-06	5.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCB1—epilepsy syndrome	4.39e-06	5.59e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TH—epilepsy syndrome	4.37e-06	5.57e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	4.32e-06	5.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—epilepsy syndrome	4.28e-06	5.46e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—epilepsy syndrome	4.28e-06	5.45e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—epilepsy syndrome	4.19e-06	5.34e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—epilepsy syndrome	4.18e-06	5.32e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RELA—epilepsy syndrome	4.16e-06	5.3e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—epilepsy syndrome	4.16e-06	5.3e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—epilepsy syndrome	4.08e-06	5.2e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—epilepsy syndrome	4.04e-06	5.15e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—epilepsy syndrome	3.92e-06	5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—epilepsy syndrome	3.79e-06	4.83e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—epilepsy syndrome	3.79e-06	4.83e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—epilepsy syndrome	3.75e-06	4.78e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—epilepsy syndrome	3.73e-06	4.75e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—epilepsy syndrome	3.65e-06	4.65e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—epilepsy syndrome	3.65e-06	4.64e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—epilepsy syndrome	3.63e-06	4.63e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAT—epilepsy syndrome	3.6e-06	4.59e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—epilepsy syndrome	3.55e-06	4.52e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RELA—epilepsy syndrome	3.52e-06	4.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—epilepsy syndrome	3.45e-06	4.39e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—epilepsy syndrome	3.44e-06	4.38e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—epilepsy syndrome	3.27e-06	4.17e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—epilepsy syndrome	3.26e-06	4.15e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	3.2e-06	4.08e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—epilepsy syndrome	3.18e-06	4.06e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—epilepsy syndrome	3.17e-06	4.04e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—epilepsy syndrome	3.08e-06	3.93e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—epilepsy syndrome	3e-06	3.82e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—epilepsy syndrome	2.91e-06	3.7e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—epilepsy syndrome	2.86e-06	3.64e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—epilepsy syndrome	2.8e-06	3.56e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—epilepsy syndrome	2.76e-06	3.52e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—epilepsy syndrome	2.69e-06	3.43e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—epilepsy syndrome	2.4e-06	3.06e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—epilepsy syndrome	2.32e-06	2.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—epilepsy syndrome	2.19e-06	2.79e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—epilepsy syndrome	2.1e-06	2.68e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—epilepsy syndrome	2.03e-06	2.59e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—epilepsy syndrome	1.92e-06	2.44e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—epilepsy syndrome	1.72e-06	2.19e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—epilepsy syndrome	9.63e-07	1.23e-05	CbGpPWpGaD
